½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

    »¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

    021-54845833/15800441009

    Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

    µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > ÆäËû¿¹Ìå > BCL9¿¹Ô­£¨ÖØ×éµ°°×£©

    ²úÆ·ÖÐÐÄ

    ×îвúÆ·

    • BCL9¿¹Ô­£¨ÖØ×éµ°°×£©

      ¹æ¸ñ£º
      ¼Û¸ñ£º£¤
      • Æ·ÅÆ : ͨεÉúÎï
      • Ŀ¼ºÅ : TW16290
      • Ó¦Óà : ½öÏÞÓÚ¿ÆÑÐʹÓÃ
      • »õÆÚ : ÏÖ»õ
      • ¹æ¸ñ £º1mg/100ug
    • ÉÌÆ·ÏêÇé
    • ²Î¿¼ÎÄÏ×
    • ˵Ã÷ÊéÏÂÔØ
    • ÉÌÆ·ÆÀÂÛ0
    • Ïà¹Ø²úÆ·

    ÖÐÎÄÃû³Æ£º BCL9¿¹Ô­£¨ÖØ×éµ°°×£©

    Ó¢ÎÄÃû³Æ£º BCL9 Antigen (Recombinant Protein)

    ±ð       Ãû£º B-cell CLL/lymphoma 9; LGS

    Ïà¹ØÀà±ð£º ¿¹Ô­

    ´¢       ´æ£º Àä¶³£¨-20¡æ£©

    ¸ÅÊö

    Fusion protein corresponding to a region derived from 1227-1426 amino acids of human BCL9

    ¼¼Êõ¹æ¸ñ

    Full name:

    B-cell CLL/lymphoma 9

    Synonyms:

    LGS

    Swissprot:

    O00512

    Gene Accession:

    BC116451

    Purity:

    >85%, as determined by Coomassie blue stained SDS-PAGE

    Expression system:

    Escherichia coli

    Tags:

    His tag C-Terminus, GST tag N-Terminus

    Background:

    BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿